company profile


NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics:

• anti-CCL2/MCP-1 Spiegelmer® NOX-E36 for diabetic nephropathy
• anti-CXCL12/SDF-1 Spiegelmer® NOX-A12 for oncology
• anti-hepcidin Spiegelmer® NOX-H94 for anemia of chronic disease

The Spiegelmer platform provides the Company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team.

 

news


Press release:
Berlin, Germany, December 04, 2012
NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94: Anemia of Chronic Disease Study is Fourth Phase II Initiated by NOXXON in 2012

English version

German version


Latest publications:

• Hematopoietic stem and progenitor cell mobilization in mouse and man by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. read article
• Targeting complement component 5a promotes vascular integrity and limits airway remodeling. read article
• The effects of the anti-hepcidin Spiegelmer NOX H94 on inflammation-induced anemia in cynomolgus monkeys. read article